

The gap in safe handling of cytotoxic drugs needs to be filled in low and middle-income countries

Safe handling of cytotoxic medicines in low and middle income countries - An overview of practices

Sandrine von Grünigen^{1,2}, Antoine Geissbühler², Pascal Bonnabry^{1,3}

¹ Pharmacy, University Hospitals of Geneva, Geneva (HUG), Switzerland

² Faculty of Medicine, University of Geneva, Switzerland


³ Institute of Pharmaceutical Sciences of western Switzerland, Geneva, Switzerland

Method

- Online survey June 2018 to March 2019
- Self-assessment of the cytotoxic process using [Cyto-SAT tool](#) *
- 134 items, 10 domains evaluated
- Scoring system from 1 (no activity) to 4 (fully implemented)
- Data recorded on an online platform (www.datapharma.ch/cyto-SAT)

*a self-assessment tool previously developed through a Delphi consensus method, see Poster P-002

Participants



48
facilities
32
countries



Results

- Median % of implementation of safe practices

All domains

Preparation sub-domains

— LMIC (n=48) Low-income (n=17) - - - Lower middle-income (n=18) - - - Upper middle-income (n=13)



- 73% of overall implementation of safe practices (Q1 49; Q3 83)
- High differences in practices between low-income and upper middle-income countries
- **Participants suggested training, mentoring and collaboration as a support to improve practices**